NEUROPATHIX, INC.
NEUROPATHIX, INC. (TYGS): 4 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.7 months
D/E -1.07 · 0% dilution
Lead: Preclinical
4 candidates
N/A
N/A
A transparent, data-derived signal for NEUROPATHIX, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$102K
Quarterly Burn
$114K
Runway
2.7 mo
Revenue
$208K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in NEUROPATHIX, INC.'s pipeline?
NEUROPATHIX, INC. (TYGS) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NEUROPATHIX, INC.'s lead drug candidate?
NEUROPATHIX, INC.'s most advanced tracked candidate is atopidine (Preclinical) for Inflammatory disorders like eczema, psoriasis, radiation dermatitis and excessive UVB radiation.
What is NEUROPATHIX, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NEUROPATHIX, INC. has approximately 2.7 months of cash runway.
Get the full picture on NEUROPATHIX, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.